Loading patent…
AssigneeSusavion Biosciences, Inc.
InventorsLaura L. Eggink, J. Kenneth Hoober
Estimating the term…
The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject.
A method of treating an immunocompromised subject, the method comprising:
A method of treating a subject having cancer and/or a viral infection:
A method of treating a subject having cancer:
The method of any one of the proceeding claims, wherein the multivalent structured polypeptide is administered to the subject and is branched.
The method of any one of the proceeding claims, wherein the therapeutic peptide or multivalent structured polypeptide stimulates proliferation of immune cells selected from the group consisting of macrophages;
The method of any one of the proceeding claims, further comprising determining (a) the level of immune cells in the subject before administering the composition;
The method of any one of the proceeding claims, wherein the therapeutic peptide or multivalent structured polypeptide activates the immune cells by binding to the inhibitory siglec receptors.
The method of any one of the proceeding claims, wherein the therapeutic peptide or multivalent structured polypeptide activates the immune cells by binding to at least one activating receptor selected from the group consisting of:
The method of any one of the proceeding claims, further comprising administering to the subject a second therapeutic peptide or a multivalent structured polypeptide comprising multiple copies of the second therapeutic peptide.
The method of any one of the proceeding claims, wherein the therapeutic peptide or multivalent structured polypeptide is in a composition comprising a carrier.
A therapeutic composition comprising a carrier, a therapeutic peptide or a multivalent structured polypeptide comprising multiple copies of the therapeutic peptide, wherein the therapeutic peptide is NQHTPR (SEQ ID NO:5), wherein the therapeutic peptide or multivalent structured polypeptide is in an amount sufficient to treat the cancer in a subject;
Dependencies are inferred from the claim text.